The Beauty Health Company Class A Common Stock Q3 2025 Earnings Recap

SKIN Q3 2025 November 8, 2025

Get alerts when SKIN reports next quarter

The Beauty Health Company reported Q3 2025 net sales of $70.7 million, a 10.3% decrease year-over-year, attributed primarily to reduced device sales and ongoing transitions in the China market.

Earnings Per Share Miss

$-0.09 vs $-0.08 est.

-12.5% surprise

Revenue Miss

70655000 vs 78064720 est.

-9.5% surprise

Market Reaction

1-Day +0.0%

5-Day -7.14%

30-Day +13.57%

See SKIN alongside your other holdings

Add to your portfolio — free

Key Takeaways

Device revenues fell 24.6% to $20.8 million, reflecting global sales pressure and a shift to a distributor model in China.
Consumables represented 71% of total sales, up from 65% a year prior, with stability seen once China’s impact is excluded.
Adjusted EBITDA rose 11% year-over-year to $8.9 million, highlighting effective cost control despite revenue declines.
Inventory levels reached their lowest in three years at under $60 million thanks to improved demand planning.
The company raised its adjusted EBITDA guidance for the remainder of 2025, indicating positive momentum entering 2026.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit SKIN on AllInvestView.

Next Q1 2026